Amyloidosis and POEMS syndrome

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 9, 2010, Pages 1501-1514

  Chee, Cheng E ^a   Dispenzieri, Angela ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amyloidosis; Bortezomib; Castleman's disease; Lenalidomide; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Osteosclerotic multiple myeloma; Paraneoplastic syndrome; POEMS syndrome; Stem cell transplantation; Thalidomide

Indexed keywords

AFLIBERCEPT; ALBINTERFERON ALPHA2B; ALPHA INTERFERON; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID; ARGATROBAN; BEVACIZUMAB; BORTEZOMIB; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; M PROTEIN; MELPHALAN; POMALIDOMIDE; PREDNISONE; RETINOIC ACID; STRONTIUM 89; TAMOXIFEN; THALIDOMIDE; TICLOPIDINE; VASCULOTROPIN ANTIBODY;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADJUVANT THERAPY; ADVANCED CANCER; AMYLOIDOSIS; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTIFICIAL VENTILATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BONE SCINTISCANNING; BRADYCARDIA; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR DISEASE; CHEMOTHERAPY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTED TOMOGRAPHY SCANNER; CREATININE BLOOD LEVEL; CYTOPENIA; DEEP VEIN THROMBOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE REGISTRY; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EDEMA; ELECTROMYOGRAPHY; ELECTROPHORESIS; ENDOCRINE FUNCTION TEST; FATIGUE; FOLLOW UP; GUILLAIN BARRE SYNDROME; HEALTH CARE ORGANIZATION; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERCALCEMIA; HYPERPIGMENTATION; LABORATORY TEST; LEUKEMIA; LONG TERM CARE; LOW DRUG DOSE; LUNG FUNCTION TEST; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE ACTION POTENTIAL; MYELODYSPLASTIC SYNDROME; NERVE POTENTIAL; NEUROLOGIC EXAMINATION; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; OSTEOSCLEROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PHYSIOTHERAPY; PLASMAPHERESIS; POEMS SYNDROME; POLYCYTHEMIA; POLYNEUROPATHY; PRACTICE GUIDELINE; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; QUALITY OF LIFE; RASH; RELAPSE; REVIEW; SENSORY NERVE; SKIN ALLERGY; STEM CELL TRANSPLANTATION; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; SYNCOPE; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT RESPONSE; X RAY DIFFRACTION;

ALKYLATING AGENTS; AMYLOIDOSIS; DIAGNOSIS, DIFFERENTIAL; HUMANS; POEMS SYNDROME; PROGNOSIS; STEM CELL TRANSPLANTATION;

EID: 77952721786     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003769874     Document Type: Review

References (97)

1. Comenzo RL. How I treat amyloidosis. Blood 2009;114:3147-3157
2. Miyazaki D, Yazaki M, Gono T, et al. AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: a case report. Amyloid 2008;15:125-128
3. Baden EM, Sikkink LA, Ramirez-Alvarado M. Light chain amyloidosis -- current findings and future prospects. Curr Protein Pept Sci 2009;10:500-508
4. Ionescu-Zanetti C, Khurana R, Gillespie JR, et al. Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy. Proc Natl Acad Sci U S A 1999;96:13175-13179
5. Sorgjerd K, Klingstedt T, Lindgren M, et al. Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture. Biochem Biophys Res Commun 2008;377:1072-1078
6. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14:3219-3230
7. van G II, van Rijswijk MH, Bijzet J, et al. Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica 2009;94:1094-1100
8. Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, et al. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med 2007;48:865-872
9. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-1207
10. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996;100:290-298
11. Gertz MA, Lacy MQ, Lust JA, et al. Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. Haematologica 2008;93:1402-1406
12. Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica 2009;94:1044-1048
13. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem-cell transplantation. Blood 2004;103:2936-2938
14. Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007;110:787-788
15. Palladini G, Russo P, Foli A, et al. Treatment with oral melphalan and dexamethasone of an extended patient population with AL amyloidosis [abstract #3889]. Blood (ASH Annual Meeting Abstracts) 2009;114:3889
16. Sanchorawala V, Wright DG, Seldin DC, et al. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 2002;117:886-889
17. Sanchorawala V, Seldin DC, Sloan JM, et al. Oral cyclic melphalan and dexamethasone in the treatment of patients with AL amyloidosis; ineligible for high-dose melphalan and stem-cell transplantation [abstract#1883]. Blood (ASH Annual Meeting Abstracts) 2009;114:1883
18. Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996;88:2801-2806
19. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998;91:3662-3670
20. Seldin DC, Anderson JJ, Sanchorawala V, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation. Blood 2004;104:1888-1893 (Pubitemid 39202302)
21. Seldin DC, Anderson JJ, Skinner M, et al. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem-cell transplantation in patients over age 65. Blood 2006;108:3945-3947
22. Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007;92:1415-1418
23. Leung N, Slezak JM, Bergstralh EJ, et al. Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem-cell transplantation. Am J Kidney Dis 2005;45:102-111 (Pubitemid 40038050)
24. Porrata LF, Gertz MA, Litzow MR, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem-cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005;11:1210-1218
25. Leung N, Leung TR, Cha SS, et al. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem-cell transplantation in AL amyloidosis patients. Blood 2005;106:3353-3357
26. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem-cell transplantation. Blood 2006;107:3378-3383
27. Comenzo RL, Gertz MA. Autologous stem-cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-4282
28. Goodman HJ, Gillmore JD, Lachmann HJ, et al. Outcome of autologous stem-cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006;134:417-425
29. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem-cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002;113:549-555
30. Saba N, Sutton D, Ross H, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem-cell transplant. Bone Marrow Transplant 1999;24:853-855
31. Kumar S, Dispenzieri A, Lacy MQ, et al. High incidence of gastrointestinal tract bleeding after autologous stem-cell transplant for primary systemic amyloidosis. Bone Marrow Transplant 2001;28:381-385
32. Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem-cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004;34:1025-1031
33. Vesole DH, Perez WS, Akasheh M, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 2006;81:880-888
34. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083-1093
35. Kumar S, Dispenzieri A, Gertz MA. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2008;358:91,92,93
36. Comenzo RL. Systemic immunoglobulin light-chain amyloidosis. Clin Lymphoma Myeloma 2006;7:182-185
37. Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem-cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008;143:369-373
38. Schonland S, Hegenbart U, Benner A, et al. Prospective Phase II study using dexamethasone induction therapy and high-dose melphalan chemotherapy followed by autologous stem-cell transplantation in 30 patients with systemic AL amyloidosis [abstract #3401]. Blood (ASH Annual Meeting Abstracts) 2009;114:3401
39. Madan S, Kumar S, Dispenzieri A, et al. Outcomes with high dose therapy and peripheral blood stem-cell transplantation for light chain (AL) amyloidosis with cardiac involvement [abstract #534]. Blood (ASH Annual Meeting Abstracts) 2009;114:534
40. Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003;3:241-246
41. Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003;10:257-261
42. Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005;105:2949-2951
43. Palladini G, Russo P, Lavatelli F, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 2009;88:347-350
44. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a Phase 2 trial. Blood 2007;109:492-496
45. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465-470 (Pubitemid 46105939)
46. Dispenzieri A, Lacy M, Zeldenrust SR, et al. long term follow-up of patients with immunoglobulin light chain amyloidosis treated with lenalidomide and dexamethasone [abstract #1737]. Blood (ASH Annual Meeting Abstracts) 2008;112:1737
47. Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly-diagnosed light-chain (AL)- amyloidosis: a multicenter Phase I/II dose escalation study [abstract #427]. Blood (ASH Annual Meeting Abstracts) 2009;112:427
48. Sloan JM, Sanchorawala V, Girnius S, et al. Melphalan, lenalidomide, and dexamethasone combination therapy in patients with AL amyloidosis [abstract #1859]. Blood (ASH Annual Meeting Abstracts) 2009;114:1859
49. Kastritis E, Roussou M, Migkou M, et al. A Phase I/II study of lenalidomide (R) with low dose dexamethasone (d) and cyclophosphamide (C) for patients with primary systemic (AL) amyloidosis [abstract #428]. Blood (ASH Annual Meeting Abstracts) 2009;114:428
50. Palladini G, Russo P, Bragotti LZ, et al. A Phase II trial of cyclophosphamide, lenalidomide and dexamethasone (CLD) in previously treated patients with AL amyloidosis [abstract #2863]. Blood (ASH Annual Meeting Abstracts) 2009;114:2863
51. Kumar S, Hayman SR, Buadi F, et al. A Phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis [abstract #3853]. Blood (ASH Annual Meeting Abstracts) 2009;114:3853
52. Sterz J, von Metzler I, Hahne JC, et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008;17:879-895
53. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 2007;92:1302-1307
54. Wechalekar AD, Lachmann HJ, Offer M, et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/ refractory clonal disease. Haematologica 2008;93:295-298
55. Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a Phase 1 dose-escalation study. Blood 2009;114:1489-1497
56. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351-1358
57. Lamm W, Willenbacher W, Zojer N, et al. efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis [abstract #2871]. Blood (ASH Annual Meeting Abstracts) 2009;114:2871
58. Landau H, Hassoun H, Cohen AD, et al. Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem-cell transplant in systemic light-chain amyloidosis (AL): a Phase II study. Blood ASH Annual Meeting Abstracts 2009;114:533
59. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010;28(6):1031-1037 [Epub ahead of print]
60. Dispenzieri A, Gertz MA, Hayman SR, et al. A pilot study of pomalidomide and dexamethasone in previously treated light chain amyloidosis patients [abstract #3854]. Blood (ASH Annual Meeting Abstracts) 2009;114:3854
61. Dispenzieri A. POEMS syndrome. Blood Rev 2007;21:285-299
62. Martin S, Labauge P, Jouanel P, et al. Restricted use of Vlambda genes in POEMS syndrome. Haematologica 2004;89:ECR02
63. Nakaseko C, Abe D, Takeuchi M, et al. Restricted oligo-clonal usage of monoclonal immunoglobulin {lambda} light chain germline in POEMS syndrome. ASH Annual Meeting Abstracts 2007;110:2483
64. Aravamudan B, Tong C, Lacy MQ, et al. Immunoglobulin variable light chain restriction, cytokine expression and plasma cell-stromal cell interactions in POEMS syndrome patients. ASH Annual Meeting Abstracts 2008;112:2744
65. Bryce AH, Ketterling RP, Gertz MA, et al. Cytogenetic analysis using multiple myeloma targets in POEMS syndrome. Proceedings of American Society of Oncology Meeting, Chicago, IL; 2007
66. Kuwabara S, Dispenzieri A, Arimura K, Misawa S. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev 2008:CD006828
67. Allam JS, Kennedy CC, Aksamit TR, Dispenzieri A. Pulmonary manifestations in patients with POEMS syndrome: a retrospective review of 137 patients. Chest 2008;133:969-974
68. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003;101:2496-2506
69. Lesprit P, Authier FJ, Gherardi R, et al. Acute arterial obliteration: a new feature of the POEMS syndrome? Medicine (Baltimore) 1996;75:226-232
70. Dupont SA, Dispenzieri A, Mauermann ML, et al. Cerebral infarction in POEMS syndrome: incidence, risk factors, and imaging characteristics. Neurology 2009;73:1308-1312
71. Sanada S, Ookawara S, Karube H, et al. Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood stem-cell transplantation. Am J Kidney Dis 2006;47:672-679
72. Gandhi GY, Basu R, Dispenzieri A, et al. Endocrinopathy in POEMS syndrome: the Mayo Clinic experience. Mayo Clin Proc 2007;82:836-842
73. Hughes RA, Bouche P, Cornblath DR, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13(4):326-332
74. Sung JY, Kuwabara S, Ogawara K, et al. Patterns of nerve conduction abnormalities in POEMS syndrome. Muscle Nerve 2002;26:189-193
75. Min JH, Hong YH, Lee KW. Electrophysiological features of patients with POEMS syndrome. Clin Neurophysiol 2005;116:965-968
76. Lesprit P, Godeau B, Authier FJ, et al. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med 1998;157:907-911
77. Nobile-Orazio E, Terenghi F, Giannotta C, et al. Serum VEGF levels in POEMS syndrome and in immune-mediated neuropathies. Neurology 2009;72:1024-1026
78. Soubrier MJ, Dubost JJ, Sauvezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS syndrome. Am J Med 1994;97:543-553
79. Nakano A, Mitsui T, Endo I, et al. Solitary plasmacytoma with VEGF overproduction: report of a patient with polyneuropathy. Neurology 2001;56:818-819
80. Mineta M, Hatori M, Sano H, et al. Recurrent Crow-Fukase syndrome associated with increased serum levels of vascular endothelial growth factor: a case report and review of the literature. Tohoku J Exp Med 2006;210:269-277
81. Dispenzieri A, Lacy MQ, Hayman SR, et al. Peripheral blood stem-cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol 2008;80:397-406
82. Kuwabara S, Misawa S, Kanai K, et al. Neurologic improvement after peripheral blood stem-cell transplantation in POEMS syndrome. Neurology 2008;71:1691-1695
83. Sinisalo M, Hietaharju A, Sauranen J, Wirta O. Thalidomide in POEMS syndrome: case report. Am J Hematol 2004;76:66-68
84. Kim SY, Lee SA, Ryoo HM, et al. Thalidomide for POEMS syndrome. Ann Hematol 2006;85:545-546
85. Kuwabara S, Misawa S, Kanai K, et al. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J Neurol Neurosurg Psychiatry 2008;79:1255-1257
86. Ohwada C, Nakaseko C, Sakai S, et al. Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndrome. Bone Marrow Transplant 2009;43:739-740
87. Dispenzieri A, Klein CJ, Mauermann ML. Lenalidomide therapy in a patient with POEMS syndrome. Blood 2007;110:1075-1076
88. Jaccard A, Abraham J, Recher C, et al. Lenalidomide therapy in nine patients with POEMS syndrome. ASH Annual Meeting Abstracts 2009;114:3872
89. Tang X, Shi X, Sun A, et al. Successful bortezomib-based treatment in POEMS syndrome. Eur J Haematol 2009;83:609-610
90. Kaygusuz I, Tezcan H, Cetiner M, et al. Bortezomib: a new therapeutic option for POEMS syndrome. Eur J Haematol 2010;84:175-177
91. Badros A, Porter N, Zimrin A. Bevacizumab therapy for POEMS syndrome. Blood 2005;106:1135
92. Straume O, Bergheim J, Ernst P. Bevacizumab therapy for POEMS syndrome. Blood 2006;107:4972-3, 4974
93. Dietrich PY, Duchosal MA. Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. Ann Oncol 2008;19:595
94. Samaras P, Bauer S, Stenner-Liewen F, et al. Treatment of POEMS syndrome with bevacizumab. Haematologica 2007;92:1438-1439
95. Straume O, Bergheim J, Ernst P, et al. Bevacizumab therapy for POEMS syndrome. Blood 2006;107:4972-4974
96. Available from: http://msmart.org/ msmart-mar09-002.htm
97. Kanai K, Kuwabara S, Misawa S, Hattori T. Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome. Intern Med 2007;46:311-313